Artificial Blood Growth Could Revolutionize Transfusions, Says Gene Therapy Expert
BUENOS AIRES – A breakthrough in cellular reprogramming is paving the way for the development of artificial blood, potentially eliminating the need for traditional blood transfusions and offering a universally safe supply, according to gene therapy specialist Dr.Martín Morgenstern. The innovation, stemming from academic research rather than pharmaceutical companies, centers on creating pathogen-free, Rh-negative blood – a universal type - from reprogrammed cells.
Morgenstern highlighted the potential disruption this technology represents, stating, “Who intends to sell a pill that serves anything?” He suggests major pharmaceutical laboratories could face challenges, while simultaneously opening notable opportunities for doctors, biochemists, biologists, and biotechnologists specializing in gene therapy. The development builds upon advancements like Yamanaka factors, which allow adult cells to revert to a pluripotent state, unlocking a range of medical applications.
A leading example of this progress is the work of israeli microbiologist Ari Gargir and his company, Red C Biotech. They are currently focused on creating this artificial blood, which would be universally compatible and free from pathogens. While still in the preclinical phase,Morgenstern emphasized the potential impact: ”This is a scientific revolution that would change the entire field of medicine.”
the expert anticipates further discussion on the intersection of cancer research and potential hindering interests in a future column, concluding with a cautionary note: “We do not believe in witches, but there are, there are.”
